Boehringer Ingelheim’s Regional Managing Director and Head of Human Pharma in the Middle East, Turkey, and Africa (‘META’) Mohammed Al-Tawil reflects on more than two decades of his career with the organization. Underlining the benefits of being a family-owned company, Tawil explains why Boehringer Ingelheim continues to invest in META, how the company managed to achieve 25.8 percent growth in Saudi Arabia in 2020, and why its portfolio in stroke, cardiovascular diseases, metabolic diseases, and pulmonary fibrosis meets the requirements of patients in the region.
Saudi Arabia is one of the most important and strategic markets in the region. The Kingdom is clearly committed to bettering the health of its citizens by continually improving its healthcare infrastructure and services, and striving for regional and global excellence
